Detalhe da pesquisa
1.
Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.
Bioorg Med Chem Lett
; 25(4): 948-51, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25577039
2.
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers.
Bioorg Med Chem Lett
; 25(4): 936-9, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25595681
3.
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.
Bioorg Med Chem Lett
; 25(4): 940-3, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25597006
4.
Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.
Bioorg Med Chem Lett
; 25(4): 944-7, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25577041
5.
Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy.
Bioorg Med Chem Lett
; 24(9): 2177-81, 2014 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24685546
6.
Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase.
Bioorg Med Chem Lett
; 20(9): 2828-31, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20356737
7.
Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV.
ACS Med Chem Lett
; 6(7): 822-6, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26191374
8.
Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability.
J Med Chem
; 57(21): 8792-816, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25317480
9.
Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.
ACS Med Chem Lett
; 5(3): 240-3, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900811
10.
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
J Med Chem
; 51(17): 5243-63, 2008 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18690678
11.
Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
Antimicrob Agents Chemother
; 51(2): 657-66, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17116675
12.
In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class.
Antimicrob Agents Chemother
; 50(4): 1228-37, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16569833